Dr. Andreadis on the Current State of CAR T-Cell Therapy in Lymphoma
January 22nd 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.
Dr. Wolf Emphasizes the Importance of Maintenance Therapy in Patients With Myeloma
January 18th 2018Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, details the role maintenance therapy has in treating patients with myeloma.
Rugo Covers Scope of Recent Breast Cancer Advances
December 6th 2017Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.
Dr. Melisko on Duration of Aromatase Inhibitor Use in Breast Cancer
November 21st 2017Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), explains the discussion around duration of use of aromatase inhibitors in patients who have estrogen receptor-positive breast cancer.
Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer
November 1st 2017Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.
Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer
October 31st 2017Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.
Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC
May 11th 2017Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).
Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer
April 7th 2017Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.
Dr. Rassiwala on Results of "All-comers" Downstaging Protocol
January 17th 2017Jasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.
Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer
January 14th 2017Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.
Dr. Venook on Important Factors for Treating Patients With CRC
December 20th 2016Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses important factors for oncologists to consider when treating patients with colorectal cancer.
Dr. Venook on Immunotherapy Potential in Colorectal Cancer
December 15th 2016Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
October 14th 2016Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.
Dr. Venook on Looking Ahead at Treatment for CRC
October 11th 2016Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer.